5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris
This study has been completed.
Sponsor:
University of Miami
Collaborator:
Ikeno Clinic
Information provided by:
University of Miami
ClinicalTrials.gov Identifier:
NCT00714454
First received: July 3, 2008
Last updated: July 11, 2008
Last verified: July 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
12-week study to compare the efficacy and safety of a course of a twice daily treatment with APS in the form of a lotion to its vehicle for the treatment of acne.
| Condition | Intervention |
|---|---|
|
Acne Vulgaris |
Other: APS Topical Lotion Other: Placebo |
| Study Type: | Interventional |
| Official Title: | 5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris: A Double-Blind, Placebo Controlled Trial |
Resource links provided by NLM:
Further study details as provided by University of Miami:
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: APS | Other: APS Topical Lotion |
| Placebo Comparator: Vehicle | Other: Placebo |
Eligibility| Ages Eligible for Study: | 18 Years to 39 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Subject has read, understood, and signed appropriate informed consent, photo consent, and HIPAA consent in their own language.
- Subject has visible mild to severe acne, as assessed by the investigator.
- Subject will be available and willing to return for follow-up visits.
- Subject agrees not to use any other acne treatment products during the study.
- Subject is otherwise healthy, non-febrile, and is not suffering from an infection likely to require antibiotic therapy during the study period.
- Subject or guardian must be able to understand the new HIPAA regulations and sign the HIPAA form.
- Subject is between the ages of 18 and 39.
- Subject agrees and understands that APS or its vehicle is to be applied to the subject twice daily for 12 weeks; no other topical or systemic medication affecting the course of acne and/or evaluability is to be used during the study.
- Subject agrees to use only the cleanser, moisturizer with sunscreen, and treatment provided by the study site for the duration of the study.
- Subject understands and agrees that he/she can not be treated with a systemic antibiotic for acne during the study.
- Subject agrees he/she will not use an acne topical treatment for two weeks prior to Day 0.
Exclusion Criteria:
- Subject or guardian has not signed informed consent, photo consent or HIPAA form.
- Subject is suffering from a condition likely to require medical attention, including administration of oral or systemic antibiotics, oral or systemic corticosteroids, or any other treatment which in the opinion of the investigator could influence the results of the study.
- Subject is pregnant or lactating.
- Subject is suffering from an abnormal skin condition not usually associated with acne.
- Subject will not be available for follow-up visits.
- Subject has been previously enrolled in any clinical study in which treatment was received within the past 30 days.
- Subjects without comedones, papules, pustules, or nodules.
- Subject has a history of hypersensitivity to any other ingredients of the study lotion.
- Subject has a history of anaphylaxis.
- Subject is not able to avoid excessive sun exposure.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00714454
Locations
| United States, Florida | |
| University of Miami Cosmetic Center | |
| Miami Beach, Florida, United States, 33140 | |
Sponsors and Collaborators
University of Miami
Ikeno Clinic
Investigators
| Principal Investigator: | Heather Woolery-Lloyd, MD | University of Miami |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00714454 History of Changes |
| Other Study ID Numbers: | 97269358-APS |
| Study First Received: | July 3, 2008 |
| Last Updated: | July 11, 2008 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Acne Vulgaris Acneiform Eruptions Skin Diseases Facial Dermatoses Sebaceous Gland Diseases Ascorbate-2-phosphate Ascorbic Acid Antineoplastic Agents Therapeutic Uses |
Pharmacologic Actions Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Vitamins Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on June 18, 2013